COMMUNIQUÉS West-GlobeNewswire

Valneva publie un très bon chiffre d'affaires 2017 soutenu par une croissance à deux chiffres des ventes de produits

15/02/2018 - 07:01

Valneva publie un très bon chiffre d'affaires 2017 soutenu par une croissance à deux chiffres des ventes de produits Forte croissance des ventes en 2017 (chiffres non audités) Chiffre d'affaires total de €109,8 millions [...]

Addex Launches CHF40 million Capital Increase with Commitment from Specialist US Healthcare Investors

15/02/2018 - 07:01

Proceeds will extend cash runway through 2022 and fund dipraglurant through the first pivotal registration study in PD-LID Geneva, Switzerland, 15 February 2018 - Addex Therapeutics (SIX: ADXN), the leading developer of [...]

Targovax ASA: Fourth quarter and full year 2017 results

15/02/2018 - 07:01

Oslo, Norway, 15 February 2018 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, today announces its third quarter 2017 results. A meeting for [...]

Addex Launches CHF40 million Capital Increase with Commitment from Specialist US Healthcare Investors

15/02/2018 - 07:01

Proceeds will extend cash runway through 2022 and fund dipraglurant through the first pivotal registration study in PD-LID Geneva, Switzerland, 15 February 2018 - Addex Therapeutics (SIX: ADXN), the leading developer of [...]

MDxHealth Notice of Financial Year 2017 Results

15/02/2018 - 07:01

COMPANY ANNOUNCEMENT REGULATED INFORMATION INSIDE INFORMATION MDxHealth Notice of Financial Year 2017 Results Conference call for analysts and investors to be held on 22 February 2018 at 15:00 CET IRVINE, CA, and [...]

Avis de publication des résultats financiers de MDxHealth pour l'exercice 2017

15/02/2018 - 07:01

ANNONCE D'ENTREPRISE INFORMATIONREGLEMENTAIRE INFORMATION PRIVILEGIEE Avis de publication des résultats financiers de MDxHealth pour l'exercice 2017 Une conférence téléphonique pour les analystes et les investisseurs [...]

PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")

15/02/2018 - 07:01

REGULATED INFORMATION GHENT, Belgium, 15 February 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major [...]

Santhera Obtains Worldwide Exclusive License from Polyphor to Develop and Commercialize Clinical Stage Candidate for Cystic Fibrosis and Other Pulmonary Diseases

15/02/2018 - 07:01

Pratteln, Switzerland, February 15, 2018 - Santhera Pharmaceuticals (SIX: SANN) announces that it has entered into a license agreement with Polyphor Ltd. for POL6014, a clinical stage selective inhibitor of human [...]

Arbutus Enters Exclusivity Agreement with Roivant Sciences

15/02/2018 - 02:50

VANCOUVER, British Columbia and WARMINSTER, Pa., Feb. 14, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS ), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, announced [...]

Bradmer Pharmaceuticals Announces Closing of Private Placement of Subscription Receipts and Signing of Arrangement Agreement in Connection With Proposed Business Combination Between Bradmer, Galaxy Digital and First Coin

15/02/2018 - 01:15

Private placement raises gross proceeds of approximately C$305 million to solidify Galaxy Digital’s dedicated blockchain and cryptocurrency merchant banking platform NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR [...]

Antares Pharma Announces FDA Approval of Partner’s Product Utilizing Our QuickShot Auto Injector

15/02/2018 - 00:21

EWING, N.J., Feb. 14, 2018 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS ) today announced the successful regulatory outcome of the Makena ® subcutaneous auto injector collaboration with AMAG Pharmaceuticals ( [...]

AMAG Pharmaceuticals Announces FDA Approval of Makena® (hydroxyprogesterone caproate injection) Subcutaneous Auto-Injector to Reduce the Risk of Preterm Birth in Certain At-Risk Women

15/02/2018 - 00:03

WALTHAM, Mass., Feb. 14, 2018 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG ) today announced that the U.S. Food and Drug Administration (FDA) approved the Makena® subcutaneous auto-injector drug-device [...]

TearLab Provides Updates on Its Osmolarity Test and TearLab Discovery™ Platform

14/02/2018 - 23:20

SAN DIEGO, Feb. 14, 2018 (GLOBE NEWSWIRE) -- TearLab Corporation (OTCQB:TEAR) (TSX: TLB ) (“TearLab” or the “Company”) today announced its plans to appeal a recent ruling from the Federal Court of Canada related to its [...]

Dentsply Sirona Declares Quarterly Cash Dividend

14/02/2018 - 23:00

YORK, Pa., Feb. 14, 2018 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona”) (NASDAQ: XRAY ), The Dental Solutions Company TM , announced that its Board of Directors declared a quarterly cash dividend of $0. [...]

Flexion Therapeutics to Present at the RBC Capital Markets 2018 Global Healthcare Conference

14/02/2018 - 22:30

BURLINGTON, Mass., Feb. 14, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq: FLXN ) today announced that Michael Clayman, M.D., President and Chief Executive Officer, and Dan Deardorf, Senior Vice President [...]

MyoKardia to Present at the RBC Capital Markets’ 2018 Healthcare Conference

14/02/2018 - 22:30

SOUTH SAN FRANCISCO, Calif., Feb. 14, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK ), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable [...]

MacroGenics Announces Date of Fourth Quarter and Full Year 2017 Financial Results Conference Call

14/02/2018 - 22:30

ROCKVILLE, MD, Feb. 14, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for [...]

Precision Optics Corporation, Inc. Announces Operating Results for the Second Quarter and Six Months of Fiscal Year 2018

14/02/2018 - 22:30

GARDNER, Mass., Feb. 14, 2018 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (OTCQB:PEYE) (the “Company”) today announced operating results on an unaudited basis for its fiscal year 2018 second quarter and six [...]

Xtant Medical Announces Exchange of Outstanding Convertible Notes and Closing of Private Placement

14/02/2018 - 22:30

Exchange of $70.238M (plus interest) of convertible notes into 10,401,309 shares of common stock at $7.20 per share. $6.809M Private Placement representing 945,819 shares of common stock at $7.20 per share. BELGRADE, [...]